NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 - NewAmsterdam Pharma  ( NASDAQ:NAMSW ) , NewAmsterdam Pharma  ( NASDAQ:NAMS )